Drugs / FROVOCIMAB
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01671085 | Aug 2012 → Mar 2013 | hyperlipoproteinemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01618916 | Jun 2012 → Feb 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01426412 | Sep 2011 → Jun 2013 | hyperlipidemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01890967 | Jun 2013 → Apr 2014 | hyperlipoproteinemia | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FROVOCIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298016 ↗ |
| Known as | LY3015014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01618916 ↗ |
| Action | Inhibit | “Subtilisin/kexin type 9 inhibitor” CHEMBL4298016 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4298016 ↗ |
| Route | Intravenous | “Administered IV over 30-90 minutes” NCT01426412 ↗ |
| Target | PCSK9 | “Subtilisin/kexin type 9 inhibitor” CHEMBL4298016 ↗ |